肝移植等待名单与移植后结局:单纯肝移植与肝肾联合移植列表的比较
本研究基于OPTN政策后2017年8月至2021年3月首次肝移植列表的成人数据,比较单纯肝移植(LTA)与肝肾联合移植(SLK)列表者的90天等待名单和1年移植后结局。在7094例成人中,90天竞争性累积等待名单死亡率在LTA合并CKD组为18.2%,LTA合并AKI组为15.3%,SLK合并AKI组为15%,SLK合并CKD组为11%(p<0.001)。移植后1年患者生存率在AKI和CKD亚组中LTA与SLK相似,但在无AKI或CKD的SLK列表者中较低。
要点
- 在列表时存在肾功能障碍的肝移植候选人中,单纯肝移植列表者应尽快接受移植以优化等待名单结局。
- SLK列表者应等待同时接受两个器官以优化移植后结局。
- 无AKI或CKD的SLK列表者1年生存率较LTA列表者差(79% vs 95%,p<0.002,校正HR 3.6,95%CI 1.3-10.3;p=0.015)。
核心结论
- 在列表时存在肾功能障碍的肝移植候选人中,单纯肝移植列表者应尽快接受移植以优化等待名单结局;SLK列表者应等待同时接受两个器官以优化移植后结局。
研究设计与样本
- 研究纳入2017年8月至2021年3月期间首次肝移植列表的成人(2628例SLK),根据列表时肾功能分层:急性肾损伤(AKI)定义为血清肌酐升高≥0.3 mg/dL或透析<42天;慢性肾脏病(CKD)定义为eGFR<60 mL/min持续≥90天或透析≥42天。
主要发现
- 在7094例成人中,90天竞争性累积等待名单死亡率:LTA合并CKD组(n=37)为18.2%,LTA合并AKI组(n=3337)为15.3%,SLK合并AKI组(n=2070)为15%,SLK合并CKD组(n=403)为11%,p<0.001。
- 在Fine and Gray模型中,与SLK合并CKD组相比,LTA合并AKI组的等待名单死亡风险为1.4倍。
- 移植后中位随访1年,AKI亚组中LTA与SLK的患者生存率相似(均为89%,p=0.83);CKD亚组中LTA与SLK的生存率分别为93% vs 86%(p=0.55);无AKI或CKD的SLK列表者生存率较低(93% vs 88%,p=0.02),校正风险比(95%CI)为0.7(0.4-1.2)。
- 在1024例列表时无AKI或CKD的LTA受者中,117例被列为SLK,其1年生存率较单纯肝移植列表者差(79% vs 95%,p<0.002,校正HR 3.6(1.3-10.3);p=0.015)。
临床怎么用
- 作者认为,在列表时存在肾功能障碍的肝移植候选人中,单纯肝移植列表者应尽快接受移植以优化等待名单结局。
- 作者认为,SLK列表者应等待同时接受两个器官以优化移植后结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data comparing waitlist and post-transplant outcomes of liver transplantation (LT) alone (LTA) versus simultaneous liver kidney (SLK) listings are limited. AIM: To examine 90-days waitlist and 1-year post-transplant outcomes of LT listings since Organ Procurement Transplant Network (OPTN) policy for SLK, who had cirrhosis with eGFR <30 mL/min or on dialysis at listing. METHODS: Adults (08/2017-03/2021) with first LT listing (2628 SLK) were stratified on renal function from listing: acute kidney injury (AKI): rise of serum creatinine by ≥0.3 mg/dL or <42 days hemodialysis; chronic kidney disease (CKD): eGFR <60 mL/min for ≥90 days or ≥42 days hemodialysis. RESULTS: Among 7094 adults analyzed, 90-days competing cumulative waitlist mortality was 18.2% in LTA + CKD (n = 37), 15.3% in LTA + AKI (n = 3337), 15% in SLK + AKI (n = 2070), and 11% in SLK + CKD (n = 403), p < 0.001. On fine and gray model, compared to SLK + CKD, LTA + AKI had 1.4-fold waitlist mortality. On a median post-transplant follow up of 1 year, patient survival was similar comparing LTA versus SLK for AKI (89% each, p = 0.83), for CKD (93 vs. 86%, p = 0.55), but lower in recipients listed for SLK with no AKI or CKD (93 vs. 88%, p = 0.02), adjusted hazard ratio (95% CI) of 0.7 (0.4-1.2). Among 1024 LTA recipients without AKI or CKD from listing, 117 were listed for SLK, and their 1-year survival was poorer compared to LT alone listings (79 vs. 95%, p < 0.002, adjusted HR 3.6 (1.3-10.3); p = 0.015). CONCLUSIONS: Among candidates with renal dysfunction at listing for LT, those listed for LT alone should receive transplant promptly to optimise waitlist outcomes. Those listed for SLK should wait to receive both organs to optimise post-transplant outcomes.
引用
- Singal AK, Kuo YF. Waitlist and post-transplant outcomes among candidates listed for liver transplant: Liver alone versus simultaneous liver kidney listings. Aliment Pharmacol Ther. 2023. PMID: 37702463. doi:10.1111/apt.17700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。